338 related articles for article (PubMed ID: 15103224)
21. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
22. The expression of ghrelin in somatotroph and other types of pituitary adenomas.
Wasko R; Jaskula M; Kotwicka M; Andrusiewicz M; Jankowska A; Liebert W; Sowinski J
Neuro Endocrinol Lett; 2008 Dec; 29(6):929-38. PubMed ID: 19112387
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and growth fractions of pituitary adenomas.
Yonezawa K; Tamaki N; Kokunai T
Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
[TBL] [Abstract][Full Text] [Related]
24. "Silent"corticotropinoma.
Pawlikowski M; Kunert-Radek J; Radek M
Neuro Endocrinol Lett; 2008 Jun; 29(3):347-50. PubMed ID: 18580839
[TBL] [Abstract][Full Text] [Related]
25. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas.
Zafar M; Ezzat S; Ramyar L; Pan N; Smyth HS; Asa SL
J Clin Endocrinol Metab; 1995 Dec; 80(12):3621-7. PubMed ID: 8530610
[TBL] [Abstract][Full Text] [Related]
26. Comparative immunohistochemical analysis of estrogen receptor and chromogranin-A reactivity in plurihormonal human prolactinomas.
Talan-Hranilović J; Gnjidić Z; Sajko T; Vizner B; Vrkljan M
Acta Med Croatica; 2000; 54(2):59-63. PubMed ID: 11028110
[TBL] [Abstract][Full Text] [Related]
27. [Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics].
Fedorova NS; Abrosimov AY; Dzeranova LK; Pigarova EA; Dedov II
Arkh Patol; 2018; 80(3):34-39. PubMed ID: 29927438
[TBL] [Abstract][Full Text] [Related]
28. [The relationship between cell proliferation activity and secretory activity in pituitary adenoma--a review of 63 cases].
Asano K; Kubo O; Tajika Y; Huang MC; Takakura K
No To Shinkei; 1996 Jun; 48(6):543-9. PubMed ID: 8703557
[TBL] [Abstract][Full Text] [Related]
29. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
30. Aromatase P450 expression in human pituitary adenomas.
Gonzales PH; Mezzomo LC; Ferreira NP; Roehe AV; Kohek MB; Oliveira Mda C
Neuropathology; 2015 Feb; 35(1):16-23. PubMed ID: 25410472
[TBL] [Abstract][Full Text] [Related]
31. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
32. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone.
Daneshdoost L; Gennarelli TA; Bashey HM; Savino PJ; Sergott RC; Bosley TM; Snyder PJ
J Clin Endocrinol Metab; 1993 Nov; 77(5):1352-5. PubMed ID: 8077332
[TBL] [Abstract][Full Text] [Related]
33. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
Mastronardi L; Guiducci A; Puzzilli F
BMC Cancer; 2001; 1():12. PubMed ID: 11570981
[TBL] [Abstract][Full Text] [Related]
34. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
35. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior.
Righi A; Morandi L; Leonardi E; Farnedi A; Marucci G; Sisto A; Frank G; Faustini-Fustini M; Zoli M; Mazzatenta D; Agati R; Foschini MP
Hum Pathol; 2013 Nov; 44(11):2400-9. PubMed ID: 24007691
[TBL] [Abstract][Full Text] [Related]
36. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
37. Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas.
Sanno N; Teramoto A; Sugiyama M; Itoh Y; Osamura RY
Am J Clin Pathol; 1996 Jul; 106(1):16-21. PubMed ID: 8701926
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptors in human pituitary adenomas.
Pichon MF; Bression D; Peillon F; Milgrom E
J Clin Endocrinol Metab; 1980 Oct; 51(4):897-902. PubMed ID: 7419671
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical expression of retinoid X receptor isoforms in human pituitaries and pituitary adenomas.
Sanno N; Sugawara A; Teramoto A; Abe Y; Yen PM; Chin WW; Osamura RY
Neuroendocrinology; 1997 Apr; 65(4):299-306. PubMed ID: 9143002
[TBL] [Abstract][Full Text] [Related]
40. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
